Keywords: Teva, Cocrystal Discovery, Hepatitis C, Viral disease, License, Share purchase, Investment

Teva invests $7.5 million in Cocrystal Discovery for novel hepatitis C antiviral

Article | 18 September 2011

Print This

In a further move to boost its non-generics activities, Israel’s Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) has signed ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in